Grace Capital’s Anavex Life Sciences AVXL Stock Holding History

Grace Capital’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,000	Closed	-$16K	–	211
2020 Q4	$16K	Buy	+3,000	New	+$15.8K	0.01%	243

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GLA

Great Lakes Advisors Chicago, Illinois $12.1B AUM 29.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Grace Capital's AVXL Position: Q1 2021 in Review

Grace Capital sold out of Anavex Life Sciences (AVXL) in Q1 2021, closing a stake of 3,000 shares — an estimated $16K sold.

Grace Capital first reported a position in AVXL in Q4 2020 and held it in 1 quarter. The position peaked at $16K in Q4 2020. 108 funds tracked by Wall St. Rank hold AVXL as of Q1 2021.

Grace Capital reported no remaining Anavex Life Sciences position as of Q1 2021 after selling out during the quarter.
Grace Capital sold 3,000 Anavex Life Sciences shares in Q1 2021, an estimated $16K.
Grace Capital first reported a position in Anavex Life Sciences in Q4 2020 and held it in 1 quarter.
Grace Capital's Anavex Life Sciences position peaked at $16K in Q4 2020.
108 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2021.

Based on Grace Capital's 13F filing for Q1 2021, filed 6 May 2021.